{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9"}]}],"title":"Anemia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"18"}]}],"title":"Lymphocyte count decreased"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Neutrophil count decreased"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Platelet count decreased"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"White blood cell count decreased"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Hypoalbuminemia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Alkaline phosphatase increased"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Alanine aminotransferase increased"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Serum amylase increased"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Aspartate aminotransferase increased"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Blood bilirubin increased"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Cholesterol high"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Creatine phosphokinase increased"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Creatinine increased"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Chronic kidney disease"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6"}]}],"title":"Gamma-glutamyltransferase increased"},{"categories":[{"measurements":[{"groupId":"OG000","value":"7"}]}],"title":"Hyperglycemia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Hypoglycemia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Hyperkalemia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Hypokalemia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}],"title":"Lipase increased"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Hypermagnesemia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Hypophosphatemia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"11"}]}],"title":"Hyponatremia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Hypertriglyceridemia"}],"denoms":[{"counts":[{"groupId":"OG000","value":"88"}],"units":"Participants"}],"description":"The laboratory measurements included hematology, liver function and blood chemistry. Number of participants with clinically significant abnormalities with Grade greater than or equals to (\\>=) 3 in laboratory values reported as TEAEs were reported. Clinically Significance was decided by investigator.","groups":[{"description":"Participants with metastatic Merkel cell carcinoma (MCC) after failing first-line chemotherapy received Avelumab at a dose of 10 milligram per kilogram (mg/kg) as 1-hour intravenous infusion once every 2 weeks until therapeutic failure, significant clinical deterioration, unacceptable toxicity, or any criterion for withdrawal from the trial or investigational medicinal product occurs.","id":"OG000","title":"Part A: Avelumab"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Safety analysis set included all participants who received at least 1 dose of study treatment.","reportingStatus":"POSTED","timeFrame":"Up to 325 weeks","title":"Part A: Number of Participants With Clinically Significant Abnormalities in Laboratory Values Reported as Treatment Emergent Adverse Events (TEAEs)","type":"SECONDARY","unitOfMeasure":"Participants"}